Search Results

You are looking at 71 - 80 of 299 items for :

Clear All
Full access

In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma that appeared in the October issue of JNCCN ( JNCCN 2011;9:1146-1183), an error appears in the Lenalidomide as Maintenance Therapy After Autologous SCT

Full access

Joyce LaMori, Kai Zu, Kristina L. Greenwood, Besa Smith, Tyler Smith and Alaina Lee

Background: This study evaluated risk factors predicting unplanned 30-day acute service utilization among adult inpatients subsequent to initial hospitalization for a new diagnosis of leukemia, lymphoma, or myeloma, with a focus on social

Full access

.2011.0093 Surgery for Early-Stage Small Cell Lung Cancer Schneider Bryan J. a MD Saxena Ashish a MD Downey Robert J. b MD 10 2011 9 9 10 10 1132 1132 1139 1139 0091132 10.6004/jnccn.2011.0094 Multiple Myeloma Anderson Kenneth

Full access

Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open-label phase I dose-escalation safety study of bortezomib in combination with pralatrexate in patients with

Full access

Alok A. Khorana

opposed to outpatient thromboprophylaxis, with the exception of IMid-based regimens in patients with myeloma, because it has not been shown to improve survival, because prophylaxis may be expensive and because of concerns regarding extrapolation to larger

Full access

/Refractory Multiple Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open-label, phase I, dose-escalation safety study of bortezomib in combination with pralatrexate in patients

Full access

A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open

Full access

Constantine S. Mitsiades and Kenneth C. Anderson

marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies . Hematol Oncol Clin North Am 2007 ; 21 : 1007 - 1034 , vii–viii . 5. Jones PA Baylin SB . The fundamental role

Full access

1426 jnccn101419 10.6004/jnccn.2019.5036 Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last? Efebera Yvonne A. MD, MPH Shah Nina MD 11 2019 17 17 11.5 11.5 1430 1430 1432 1432 jnccn20195033 10

Full access

Robert W. Carlson

follicular lymphoma. Between these sessions, a second debate evaluated the appropriate length of initial treatment of multiple myeloma. The congress also included 3 interactive sessions featuring patient case studies and panel discussions. In the first